CNXC Concentrix Corp Insider Trading

CEO Caldwell buys 1,000 CNXC shares at $21.25; stock now $20.97, down 66.2% from 52-week high of $62.14.

Christopher A Caldwell, President and CEO of Concentrix Corp, purchased 1,000 shares at $21.25 on 2026-07-08, increasing his holdings from 357,382 to 358,382 shares. The purchase occurred during a period of significant market weakness: CNXC has declined 66.2% from its 52-week high of $62.14 and is down 23.2% over the past 30 days. Caldwell's prior five buys at this ticker show a 0 of 5 win rate at the 90-day mark, with purchases made on 2026-03-26, 2026-01-29, 2025-10-31, 2025-10-30, and 2025-10-10 all followed by negative 90-day returns ranging from −2.8% to −33.0%. The company's fundamentals show recent quarterly revenue of $2,462,473,000.00 with net income of $55,276,000.00, though full-year results were unprofitable, and annual revenue growth stands at +2.2%.

Major 10% shareholder Groupe Bruxelles Lambert liquidates 68% stake in Concentrix amid steep stock decline.

Groupe Bruxelles Lambert, a large institutional holder with nearly 69% ownership position, sold a substantial block of shares at a time when Concentrix stock has deteriorated significantly from its highs and is currently trading near recent lows. This is a portfolio management decision rather than insider conviction—the filer has no operational role at the company and is simply adjusting its position. However, the timing is noteworthy: the institution chose to execute this liquidation while the stock was already under pressure, and the company's latest results show a return to profitability at the quarterly level despite an annual loss and limited revenue growth. The combination of institutional deleveraging on a weak stock and mixed financial health suggests the holder may be repositioning risk rather than expressing confidence in near-term recovery.

CFO Valentine Andre S bought 2,500 shares of CNXC at $27.95 on 2026-04-09, boosting holdings to 89,066 shares amid 35.3% 90-day decline

CFO Valentine Andre S purchased 2,500 shares of Concentrix Corp at $27.95, representing a +2.9% increase to his holdings. The transaction occurs in the context of significant price erosion: the stock is -54.0% from its 52-week high and has declined 35.3% over the past 90 days, notably falling 11.6% in the most recent 30 days. This timing coincides with structural headwinds at the company: while Revenue remains substantial at $2,500,391,000.00 ($2.5B) in the latest quarter, the company was unprofitable over its most recent full fiscal year and has grown annual revenue only 2.2% year-over-year. The purchase warrants tracking to determine whether the timing reflects a conviction accumulation at depressed valuation levels or merely routine portfolio activity by a capital-allocation officer.

CEO Christopher A Caldwell buys 1,000 CNXC shares at $26.97 amid -59.0% decline from 52-week high

Caldwell, as President and CEO, purchased 1,000 shares of Concentrix Corp at $26.97 on 2026-03-26, a modest addition to his 357.4K share position. The purchase occurs while CNXC trades -59.0% from its 52-week high of $65.04, and after a -36.1% decline over the past 90 days. However, his historical performance at this ticker raises concerns: across his 5 prior trades at CNXC, none of the 4 measurable buys were well-timed at the 90-day mark, with 90-day returns of -11.5%, -9.5%, -13.8%, -23.4%, and -13.6%. The company's fundamentals remain challenged, having posted negative full-year net income in its most recent fiscal year despite $2.5B in quarterly revenue. The timing signal is weak: this buy follows a pattern of similarly-timed purchases that have consistently underperformed post-acquisition, suggesting the CEO's open-market conviction at depressed valuations has not translated into positive subsequent returns in this name.

CNXC President/CEO buys 1,000 shares at $37.07; stock down -39.0% from 52-week high and unprofitable last fiscal year.

Caldwell Christopher A, President and CEO of Concentrix Corp (CNXC), purchased 1,000 shares at $37.07 on 2026-01-29, increasing his holdings to 362,075 shares (362.1K shares). The transaction occurs in a materially depressed valuation context: CNXC trades at $39.67, representing -39.0% from its 52-week high of $65.04, and the company reported a negative net income over its most recent full fiscal year despite $2.5B in quarterly revenue. His prior purchases at this same ticker exhibit a poor timing pattern, with only 1 of 5 prior buys showing positive 90-day returns (80% failure rate). The current purchase at a price below the 52-week range midpoint could indicate opportunistic accumulation, but the persistent unprofitability and his repeated unsuccessful prior accumulation attempts at CNXC during weakness warrant scrutiny of whether this reflects informed confidence or mechanical rebalancing.

CNXC President/CEO Caldwell buys 1,000 shares at $40.00 as stock trades 39.1% below 52-week high

Christopher A Caldwell, President and CEO of Concentrix Corp, purchased 1,000 shares at $40.00 on 2025-10-31, increasing his holdings from 286.7K to 287.7K shares. The purchase occurs as the stock trades at $39.60, down 39.1% from its 52-week high of $65.04 and down 17.9% over the prior 30 days. This represents the CEO's third consecutive buy in as many days (following purchases on 2025-10-30 and 2025-10-10), following a similar buy pattern during the same September-October period at this ticker. At current prices, the stock trades at a P/E of 7.80 against annual revenue growth of 35.2% and a market cap of $2.5B, suggesting a compressed valuation relative to growth fundamentals. The concentrated buying sequence warrants attention to whether management views the recent 39.1% drawdown as providing entry value after the decline.

CNXC CEO Caldwell bought 2,000 shares at $42.03 on 2025-10-30, building holdings to 286,661 shares amid 38% decline from 52-week high.

CEO Christopher A Caldwell purchased 2,000 shares at $42.03 on 2025-10-30, expanding his stake to 286,661 shares. The purchase occurs after a significant contraction in CNXC's valuation: the stock is currently $40.31, down 38.0% from its 52-week high of $65.04 and down 16.4% in the trailing 30 days. Across his prior open-market transactions at this ticker (5 distinct prior trades), Caldwell's buy at $42.03 sits above current price, following a recent buy on 2025-10-10 whose 90-day outcome is not yet measurable and another on 2025-10-31 (also not measurable). His cross-ticker track record shows 5 prior open-market buys averaging +9.0% 30-day return and +25.9% 90-day return with a 100% 90-day win rate, but measuring outcomes on fresh accumulation activity during a sharp drawdown requires patience: the stock's current -16.4% 30-day move and below-entry pricing suggest the near-term thesis has not yet validated.

CNXC CEO Christopher Caldwell purchases 1,000 shares at $45.35; stock down 30.9% from 52-week high.

Caldwell, the President and CEO, purchased 1,000 shares at $45.35 on 2025-10-10, adding to holdings of 305,345 shares post-transaction. The acquisition occurs amid significant price weakness: CNXC has fallen 30.9% from its 52-week high of $65.04 and declined 16.8% over 30 days and 19.7% over 90 days, while trading near $44.92 currently. Caldwell's prior trades at CNXC show strong execution: his 2025-04-21 buy delivered +26.8% at 90 days, his 2024-10-04 sell was well-timed (stock fell 17.4% subsequently), and his 2024-04-19 buy gained +24.9% over 90 days—a 3-of-3 pattern of well-timed activity at this ticker. Against this favorable timing backdrop, the current purchase arrives during material drawdown, though the company reports robust fundamentals: $2.5B quarterly revenue, $88.1M net income, +35.2% annual revenue growth, and a P/E of 8.84. The buy signal must be weighed against the stock's recent severe underperformance and the absence of immediate positive catalyst data.

CEO Caldwell buys 1,000 shares of CNXC at $47.44; stock now -26.4% from 52-week high, but his prior 3 trades at ticker showed 100% accuracy at 90-day mark.

President and CEO Christopher A Caldwell purchased 1,000 shares at $47.44, expanding his holdings to 304,735 shares (+0.3% increase). The purchase occurs against a backdrop of near-term weakness: the stock has declined 7.5% over 30 days and 16.3% over 90 days, trading 26.4% below its 52-week high. However, Caldwell's historical execution at CNXC is striking: his 3 prior trades at this ticker were all well-timed at the 90-day horizon, including two prior buys that generated +20.8% and +19.8% returns respectively, and one sell that was well-timed into a decline. His cross-ticker open-market history shows 2 prior buys with 100% 90-day win rate (avg +25.9% return) and 1 prior sell with 100% well-timed execution. This insider's pattern of precision timing at both this specific ticker and across his broader trading history provides a notable signal, particularly given the current depressed price relative to recent highs.

CEO Christopher Caldwell buys 1,000 CNXC shares at $46.00, extending purchase pattern in 100%-well-timed ticker trade history

Caldwell Christopher A, President and CEO of Concentrix Corp, purchased 1,000 shares at $46.00 on 2025-04-21, adding to his 303.4K share position. This buy occurs within a favorable fundamental backdrop: the company reported $2.4B revenue with +35.2% annual growth and a 11.40 P/E ratio. Notably, Caldwell's prior two trades at CNXC—a sell on 2024-10-04 and a buy on 2024-04-19—were both well-timed at the 90-day mark, with the buy posting +24.9% and the sell yielding -17.4%, establishing a pattern of consistent trade timing on this ticker. The current purchase at $46.00 follows a 6.9% rally over 30 days but remains 36.4% below the 52-week high of $75.58, positioning the transaction in a recovery context relative to recent peaks.